Colestipol

Quick links to important sections

Colestipol

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Colestipol

Property Description
Active ingredient Colestipol Hydrochloride
Form Granules (for suspension), Tablet
Pharmacological class Bile acid sequestrant (BAS)
Common use Reducing elevated LDL cholesterol
Origin Synthetic, non-absorbable polymer

What Type of Medicine is Colestipol?

Colestipol is a specific prescription medication classified as a bile acid sequestrant (BAS), which is utilized as an antihyperlipidemic agent. The drug serves as a therapy for reducing elevated serum low-density lipoprotein (LDL) cholesterol in patients with primary hypercholesterolemia. This drug is a synthetic, single-ingredient compound, chemically identified as an anion-exchange resin. This structure allows it to function as a large, non-absorbable polymer that remains active exclusively within the gastrointestinal tract, differentiating it from agents that rely on systemic absorption.

This non-systemic approach is a key feature of Colestipol, setting it apart from agents that rely on systemic absorption.


Composition, Form, and General Purpose

The active component in this medicine is Colestipol or its salt, Colestipol Hydrochloride. The substance is a high molecular weight, insoluble polymer known as a poly(allylamine) resin. It is supplied for oral administration in two distinct forms: granules intended for mixing into an oral suspension, and a compressed tablet formulation.

The drug's general purpose is to lower elevated cholesterol levels. Colestipol achieves this by physically binding the body's bile acids within the small intestine. The mechanism involves increasing the fecal excretion of bile acids, which prompts the liver to use circulating cholesterol to synthesize replacements. This process results in a reduction of plasma LDL cholesterol concentration, providing a means of managing lipid levels.

Regulatory References

  1. National Institutes of Health (NIH)
  2. Colestipol (MedlinePlus)

What side effects are possible with Colestipol?

Possible Side Effects and Safety Information

Colestipol is a bile acid sequestrant that is not absorbed into the body; therefore, its adverse reactions are primarily confined to the gastrointestinal (GI) tract.

Common Adverse Reactions

The most frequently reported adverse reaction is constipation, which can occasionally be severe and may aggravate pre-existing hemorrhoids. Other common GI effects include abdominal pain or cramping, flatulence, nausea, vomiting, and indigestion. Less commonly reported side effects include headache, dizziness, fatigue, and various musculoskeletal complaints such as arthritis or back pain.


Serious Safety Considerations

Due to its mechanism of action, colestipol can interfere with the absorption of essential substances. Chronic use may lead to a reduced absorption of fat-soluble vitamins (A, D, E, K) and folic acid. This can result in an increased bleeding tendency due to acquired hypoprothrombinemia (Vitamin K deficiency) and requires regular monitoring. The drug is contraindicated in patients with known hypersensitivity to the product or those with complete biliary obstruction.

Safety Restrictions and Monitoring

The powder and granule formulations must never be taken dry as this poses a risk of esophageal obstruction. The dosage may need to be reduced or discontinued if severe constipation occurs. Periodic determination of serum cholesterol and triglyceride levels is necessary to confirm a therapeutic response.

Overdose and Emergency Response

Colestipol Overdose and when to seek help

The official prescribing information indicates that overdosage with Colestipol has not been reported. Due to the drug's classification as a non-absorbable polymer, there is a low risk of systemic toxicity in the event of ingestion exceeding the prescribed amount.

The regulatory documents confirm that the chief potential harm that may occur should an overdosage take place is obstruction of the gastrointestinal tract. This risk relates to the localized mechanical presence of the compound within the digestive system.


Overdose Scope

Property Official Regulatory Statement
Primary Physical Risk Obstruction of the gastrointestinal tract.
Systemic Harm Low risk of systemic toxicity.

When to Seek Immediate Medical Help

The immediate need for medical assistance is triggered by severe, generalized signs consistent with any medical emergency. Urgent medical attention must be sought if a person has collapsed, experienced a seizure, or has trouble breathing or is unable to be awakened.

In the event of a suspected overdosage, the mandated action is to contact a poison control helpline or emergency services. Management is described as generally symptomatic and supportive, with specific measures directed at assessing and treating the documented mechanical complication.

Therapeutic Uses of Colestipol

What Colestipol Treats: Main Uses and Benefits

Colestipol is a bile acid sequestrant, a category of medication is commonly used to help with the management of lipid levels. Its primary use is considered relevant as adjunctive therapy to diet to help reduce elevated serum total and low-density lipoprotein cholesterol (LDL-C) in patients with primary hypercholesterolemia. This application is specifically intended for scenarios where patients are managing lipid profiles in conjunction with dietary efforts.

This medication is relevant for easing discomfort related to systemic imbalance, a condition where functional stability becomes affected. It contributes to easing the overall symptom load associated with elevated lipids and is applied in addressing the concentration of 'bad' cholesterol. Colestipol may be part of symptomatic management for patients who benefit from additional support for managing their lipid profiles, and also in situations involving certain distressing symptoms linked to organ-specific functional stress.

“This medication supports the patient during difficult episodes by easing distress related to high lipid levels.”

Quick Fact: Relief for Elevated Lipids
Colestipol is a treatment often used during phases when symptoms become more noticeable (like high cholesterol), as an addition to dietary management.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Colestipol — Official Regulatory Information

Category Official Regulatory Status
Populations for whom use is allowed (as stated in label) Adults with primary hypercholesterolemia who do not respond adequately to diet [FDA Label].
Populations for whom use is not recommended (if applicable) Infants and children under 2 years of age, as cholesterol is needed for normal development [NIH/MedlinePlus].
Populations for whom use is contraindicated Individuals with a documented hypersensitivity to Colestipol Hydrochloride or any of its components [FDA Label]. Patients with complete biliary obstruction [Canadian Labeling/Clinical Consensus].
Age-related eligibility rules Use is not established in the pediatric population; use requires caution in the geriatric population (over 60 years) due to potential for increased gastrointestinal effects.
Condition-specific eligibility rules Secondary causes of hypercholesterolemia must be excluded prior to initiating therapy [FDA Label].
Pregnancy and lactation eligibility status Pregnancy: Use requires that potential benefits be weighed against possible hazards due to known interference with fat-soluble vitamin absorption [FDA Label]. Lactation: Caution should be exercised [FDA Label].
Eligibility-related restrictions Use may not be indicated in patients with TG levels gt 400 mg/dL. Use must be monitored if pre-existing severe constipation is present or worsened, as this may aggravate hemorrhoids [FDA Label].

Connection to the Overall Eligibility Profile

Regulatory documents define who can and cannot use Colestipol through absolute contraindications concerning hypersensitivity and several conditional restrictions related to age and pre-existing conditions. The labeling designates the adult population with primary hypercholesterolemia as the approved user base, while explicitly classifying use in infants as not recommended. Use is restricted in patients with severe constipation and requires caution during pregnancy due to the non-systemic drug's effect on fat-soluble vitamin absorption.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Colestipol's official interaction profile is defined by its non-systemic activity as a bile acid sequestrant, which leads to pharmacokinetic interactions through physical binding within the gastrointestinal tract. This binding action results in the reduced systemic exposure of various co-administered oral medicines. Regulatory documentation specifies that co-administration with oral Mycophenolate is formally classified as contraindicated due to the resulting significant decrease in absorption.

The primary pattern involves the reduced absorption of several other agents, including Digoxin, Warfarin, Thyroxine, Tetracycline Antibiotics, and Gemfibrozil. To mitigate this interference with absorption, a mandatory timing separation rule applies: other oral medications must be administered at least one hour before or four hours after Colestipol.

This binding action also interferes with the absorption of essential nutrients, specifically fat-soluble vitamins (A, D, E, K) and Folic Acid. This documented reduction in nutrient exposure can lead to deficiencies, such as hypoprothrombinemia associated with Vitamin K deficiency. Separately, the flavored granule formulation contains phenylalanine, which is a documented restriction for use in patients with Phenylketonuria (PKU).

Mechanism of Action

Colestipol is a non-systemic anion-exchange resin that physically binds bile acids in the small intestine, forming an insoluble complex. This mechanism of sequestration is responsible for interrupting the enterohepatic circulation, which is the normal recycling pathway that returns bile acids from the gut back to the liver.

The accelerated loss of bile acids forces the liver to compensate by using its intracellular cholesterol stores to synthesize replacement bile acids. This depletion triggers a homeostatic mechanism that upregulates the expression of LDL receptors on the liver cell surface. This increase in receptors is the key physiological adjustment that increases the clearance of LDL cholesterol particles from the bloodstream.

By increasing the number of active LDL receptors, the mechanism results in increased catabolism (breakdown) and removal of circulating low-density lipoprotein particles. This targeted, indirect action alters the body’s lipid processing by accelerating the use of plasma LDL-C for essential metabolic processes.

Dosage and Administration Information

How to Use Colestipol

Colestipol is administered exclusively by the oral route as part of a long-term treatment plan. The medicine is available in two forms: 1-gram tablets and 5-gram granules for oral suspension.

Administration and Timing

The typical protocol involves gradual dose titration. The initial dose for adults, whether 2 grams (tablets) or 5 grams (granules), is taken once daily or divided into two daily doses. The dosage may be adjusted in small increments at 1- or 2-month intervals. The maximum daily doses are 16 grams for tablets and 30 grams for granules.

Administration Constraint Administration Guidelines
Granule Preparation Must be mixed with at least 3 ounces of liquid (e.g., water, juice, soup) and must never be taken dry.
Tablet Integrity Tablets must be swallowed whole with fluid; they must not be cut, crushed, or chewed.
Separation from Other Drugs Other oral medications should be administered one hour before or four hours after Colestipol to prevent interference with their absorption.
Missed Dose Protocol If a dose is missed, individuals should resume their regular schedule with the next dose and not take two doses at once.

Colestipol is generally intended for long-term use. Upon discontinuation, serum cholesterol levels typically return to baseline within one month. Standard clinical data does not specify a different dosage for pediatric patients, who should be dosed under specialized guidance.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Colestipol

Evidence for Use in Primary Hypercholesterolemia

Research related to Colestipol's primary studied area has primarily involved controlled clinical trials and dose-response studies that evaluated the medicine as a monotherapy. These studies were generally focused on adults diagnosed with primary moderate hypercholesterolemia. The outcomes that researchers most commonly measured were shifts in LDL-C and Total Cholesterol (TC) concentrations in the blood. Follow-up for these primary biomarker assessments was typically short-term, lasting approximately 8 to 10 weeks.

The findings from these short-term studies reported measurements of LDL-C and TC concentration during the study period. Based on the consistency of these measurements across studies, the evidence related to short-term changes in lipid biomarkers is classified as High level evidence.

There is limited information regarding long-term clinical events. Few data are available for how lipid measurements evolved after study discontinuation. Limited insight is available regarding the patterns observed in patients who have severely elevated TG levels.


Evidence from Combined Therapy and Cardiovascular Research

Colestipol was evaluated in research that assessed its use as part of a combination therapy with other lipid-altering agents. These research scenarios focused on populations with established risk factors, such as those with Coronary Heart Disease (CHD) or Familial Hypercholesterolemia (HeFH). Researchers explored outcomes related to physical changes in blood vessels over several years, using angiographic imaging to assess the progression or regression of atherosclerosis. Studies also monitored patterns related to major adverse cardiovascular events.

The evidence related to these specific cardiovascular outcomes is classified as Moderate level evidence. This assessment notes that the data were derived from combination therapy regimens, meaning the specific contribution of Colestipol within the intensive combined regimen is not fully characterized.


Long-Term Studies and Durability of Response

Research was designed to monitor observed patient measurements over defined time intervals, with follow-up periods for some studies extending up to seven years. The evidence related to long-term clinical outcomes may be inferred from the data of large trials involving other bile acid sequestrants. Research highlights patterns where lipid measurements were observed in some studies to evolve toward baseline after the study monitoring period.


What Remains Uncertain About Colestipol Research

Across the overall research landscape, the full extent of the long-term evaluation on major adverse clinical events is not characterized by pivotal trials for Colestipol itself. For research exploring investigational uses outside of lipid management, the evidence is limited, often based on small sample sizes and limited follow-up durations. Overall, the available research provides context but not individual predictions, and research is ongoing to fully characterize the long-term profile of this medicine.

Frequently Asked Questions (FAQ)

Common questions about Colestipol (FAQ)


Q: Is Colestipol the same type of drug as cholestyramine?

A: Colestipol and cholestyramine are both classified in regulatory documents as bile acid sequestrants (BAS). These medications share a similar general mechanism of action, which involves physically binding bile acids in the intestine. This mechanism is what distinguishes them from other types of cholesterol-lowering agents.


Q: What kind of changes should I expect in my diet while taking Colestipol?

A: Official guidance describes Colestipol as an adjunct to diet. This means the medicine is intended to be used alongside a special diet prescribed by a healthcare provider to help lower cholesterol. Following the dietary plan is noted in official documentation as a required component of the treatment protocol for the medication to be used as intended.


Q: Is Colestipol available as a generic drug?

A: Yes, Colestipol is available as a generic formulation, Colestipol Hydrochloride. This includes both the tablet and granule forms of the medication.


Q: Why is Colestipol sometimes prescribed if I already take a statin?

A: Regulatory documentation indicates that this medicine is used as adjunctive therapy (add-on treatment) to diet. Official documentation indicates it is used as adjunctive therapy in individuals who have not achieved the desired LDL reduction with maximally tolerated statin therapy alone.


Q: How quickly should Colestipol start to work for cholesterol levels?

A: Regulatory documents state that the measurable decline in serum cholesterol levels is usually evident by one month of treatment. Treatment is generally intended for long-term use.


Q: Why is Colestipol sometimes used for conditions other than high cholesterol?

A: Regulatory-linked medical resources describe uses for the management of pruritus (itching) that is associated with elevated bile acids. It is also mentioned for the treatment of certain types of diarrhea associated with an excess of bile acids.


Q: How does Colestipol affect triglycerides?

A: According to official product information, Colestipol generally has no clinically relevant effect on serum triglyceride concentrations in the standard patient population. However, regulatory documents advise that triglyceride levels may increase in some patients, and periodic determination of serum triglyceride levels is required to confirm therapeutic response.


Q: Does Colestipol cause constipation, and how is that managed generally?

A: Constipation is noted in official documents as the most frequently reported adverse reaction. Regulatory-linked information describing standard management includes suggestions such as increased fluid intake and the inclusion of dietary fiber. A stool softener may also be added.


Q: Does Colestipol cause heartburn?

A: Heartburn is specifically listed in regulatory documents as one of the less frequent gastrointestinal complaints reported in clinical studies of the medicine.


Q: Are there any long-term side effects that official sources describe for Colestipol?

A: Official documents note that chronic use may lead to reduced absorption of fat-soluble vitamins (A, D, E, K) and Folic Acid. This reduction in nutrient exposure is associated with the risk of deficiencies, such as hypoprothrombinemia (Vitamin K deficiency), which can lead to an increased bleeding tendency.


Q: Can I take Colestipol if I have kidney disease?

A: Because Colestipol is classified as an anion exchange resin, regulatory information suggests caution when administering the drug to patients with renal impairment (kidney disease). This is due to the potential for the development of a metabolic change known as hyperchloremic acidosis associated with chronic use.


Q: Can taking Colestipol cause issues with gallstones?

A: Cholecystitis (gallbladder inflammation) and cholelithiasis (gallstones) have been reported rarely in patients, but these conditions are not necessarily linked to the drug. Regulatory-linked information notes caution is advised for patients with pre-existing gallstones.


Q: Can Colestipol interfere with birth control pills?

A: Official information indicates that Colestipol may interfere with the absorption of certain ingredients found in oral contraceptives, such as progesterone, when taken at the same time. As a result, the mandatory timing separation rule, where other oral medications are taken either one hour before or four hours after Colestipol, applies.


Q: What does official data say about Colestipol and changes to HDL cholesterol?

A: Official data generally indicate that little change is observed in HDL cholesterol (HDL-C) levels when taking Colestipol. However, studies have noted an observed increase in a specific particle, the LpAI particle, within the HDL fraction.


Q: Why is the official guidance for use so non-specific about meal timing?

A: The official guidance allows for flexibility in timing: tablets may be taken with meals, and the granules can be mixed with various liquids or foods. The guidance emphasizes adherence to the drug separation rule to prevent interference with the absorption of other oral medications.


Q: Do official documents mention Colestipol affecting mood or sleep?

A: Regulatory documents list insomnia (difficulty sleeping) and rarely anxiety as infrequently reported non-gastrointestinal adverse reactions noted in clinical studies.


Q: Do studies suggest Colestipol has long-term cardiovascular benefits?

A: Research related to the long-term profile of Colestipol often refers to the findings from studies involving the similar bile acid sequestrant, cholestyramine. These studies reported an observed reduction in the combined rate of coronary heart disease death and nonfatal myocardial infarction over seven years.


Q: Can Colestipol be taken by someone with liver problems?

A: Colestipol is contraindicated in patients with complete biliary obstruction. For other non-obstructive liver conditions, official information requires careful consideration, particularly related to the potential risk of interactions with concurrent medications that may be affected by Colestipol's mechanism.


Q: Can Colestipol affect the body's absorption of other cholesterol medicines?

A: Yes, Colestipol may decrease the level or effect of other oral cholesterol medicines, such as the statin atorvastatin, by interfering with absorption in the gastrointestinal tract. To mitigate this effect, the mandatory drug separation rule applies.


Q: Does Colestipol need to be taken at a specific time of day?

A: For the adult population, if the dose is divided, regulatory guidance allows one dose to be taken at breakfast or lunch and a second dose in the evening. Granules are generally recommended to be taken before meals.


Q: What are the signs of a severe allergic reaction to Colestipol?

A: Hypersensitivity to Colestipol is a contraindication. Reported signs of skin reactions include rash and irritation. Official documentation notes that severe or prolonged irritation of the tongue has been described and should be reported.

How should Colestipol be stored and disposed of?

How to Store and Dispose of Colestipol?

The official storage and disposal requirements for Colestipol are defined in regulatory documents to ensure product stability and public safety.

Requirement Official Instruction
Storage Temperature Store at controlled room temperature, specifically 20 C to 25 C (68 F to 77 F) [1.1, 2.7].
Protection & Handling Keep the container tightly closed and protect the medicine from moisture, excess heat, and freezing [2.1, 2.4]. Do not store the medicine in a humid location like a bathroom [2.4].
Child Safety The medication must be kept out of the sight and reach of children and pets, and safety caps must be locked [2.4, 2.7].
Disposal Dispose of outdated or unused Colestipol through a drug take-back program [2.2, 2.7]. If a take-back program is unavailable, mix the medicine with an unappealing substance (like dirt or coffee grounds), place it in a sealed bag or container, and discard it in the household trash [1.6]. Do not flush the medicine down the toilet [1.6].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Colestipol found in:

A-Z Index: